Exscientia Yönetim

Yönetim kriter kontrolleri 1/4

Exscientia's CEO is Dave Hallett, appointed in Feb 2023, has a tenure of 1.75 years. directly owns 0.001% of the company’s shares, worth €6.78K. The average tenure of the management team and the board of directors is 1.8 years and 3.9 years respectively.

Anahtar bilgiler

Dave Hallett

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	0.001%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Dave Hallett (55 yo)

1.8yrs

Görev süresi

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallett	Chief Scientific Officer	1.8yrs	Veri yok	0.0012% € 6.8k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	4yrs	UK£1.92m	0.062% € 362.0k
John Overington	Chief Technology Officer	less than a year	Veri yok	0.015% € 88.6k
Sara Sherman	Vice President of Investor Relations	no data	Veri yok	Veri yok
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	Veri yok	Veri yok
Parker Moss	Executive Vice President of Corporate Development	less than a year	Veri yok	Veri yok
Caroline Rowland	Chief People Officer	2.2yrs	Veri yok	Veri yok
Richard Law	Chief Business Officer	no data	Veri yok	Veri yok
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	Veri yok	Veri yok
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 0RK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Hallett	Chief Scientific Officer	less than a year	Veri yok	0.0012% € 6.8k
Ben Taylor	CFO, Chief Strategy Officer & Executive Director	4yrs	UK£1.92m	0.062% € 362.0k
Elizabeth Crain	Independent Non-Executive Chairman	3.8yrs	UK£282.03k	0.089% € 520.8k
Mario Polywka	Independent Non-Executive Director	7.2yrs	UK£201.69k	0.053% € 308.6k
Robert Ghenchev	Independent Non-Executive Director	4.5yrs	Veri yok	Veri yok
Franziska Michor	Independent Director	1.5yrs	UK£178.86k	0.028% € 164.2k

3.9yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0RK's board of directors are considered experienced (3.9 years average tenure).

Exscientia Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Third quarter 2022 earnings released: UK£0.29 loss per share (vs UK£59.17 loss in 3Q 2021)

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Less than half of directors are independent

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

High number of new directors

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş